Anti-TL1A Deal Benchmarks

TL1A (TNF-like ligand 1A) has become the most sought-after novel target in gastroenterology following Merck's $10.8B acquisition of Prometheus Biosciences in 2023. Phase 2 anti-TL1A deals for Crohn's disease carry a median total deal value of $3.3B, with upfront payments of $620M. The dual mechanism — anti-inflammatory and anti-fibrotic activity — addresses a critical unmet need in IBD, as fibrosis drives surgical morbidity in Crohn's disease.

Deal structures for anti-TL1A assets reflect the transformative pipeline interest. Development milestones average $557M, with key gates tied to endoscopic remission data and fibrosis endpoints. Regulatory milestones of $663M and commercial milestones of $1.4B reward market entry in what is projected to become a $5-10B target class by 2030.

Royalty rates for anti-TL1A licensing range from 8.1% to 15.1%, with tiered escalation to 19.1%. Differentiation factors include biomarker-guided patient selection (TL1A genetic risk variants), combination potential with IL-23 inhibitors, and oral versus injectable formulation. The competitive landscape has expanded rapidly, with Roche/Genentech, Pfizer, AbbVie, and Sanofi all pursuing TL1A programs.